- Home
- MGEE vs RYTM Comparison
MGEE vs RYTM Comparison
Compare MGEE & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGEE
- RYTM
- Stock Information
- Founded
- MGEE 1855
- RYTM 2008
- Country
- MGEE United States
- RYTM United States
- Employees
- MGEE N/A
- RYTM N/A
- Industry
- MGEE Electric Utilities: Central
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- MGEE Energy
- RYTM Health Care
- Exchange
- MGEE Nasdaq
- RYTM Nasdaq
- Market Cap
- MGEE 3.8B
- RYTM 4.3B
- IPO Year
- MGEE N/A
- RYTM 2017
- Fundamental
- Price
- MGEE $88.49
- RYTM $89.00
- Analyst Decision
- MGEE Sell
- RYTM Strong Buy
- Analyst Count
- MGEE 1
- RYTM 13
- Target Price
- MGEE $74.00
- RYTM $80.08
- AVG Volume (30 Days)
- MGEE 194.3K
- RYTM 806.9K
- Earning Date
- MGEE 08-06-2025
- RYTM 08-05-2025
- Dividend Yield
- MGEE 2.05%
- RYTM N/A
- EPS Growth
- MGEE 6.51
- RYTM N/A
- EPS
- MGEE 3.54
- RYTM N/A
- Revenue
- MGEE $687,578,000.00
- RYTM $136,863,000.00
- Revenue This Year
- MGEE $9.95
- RYTM $37.56
- Revenue Next Year
- MGEE $3.02
- RYTM $74.99
- P/E Ratio
- MGEE $24.85
- RYTM N/A
- Revenue Growth
- MGEE 6.11
- RYTM 48.88
- 52 Week Low
- MGEE $75.27
- RYTM $40.61
- 52 Week High
- MGEE $109.22
- RYTM $88.99
- Technical
- Relative Strength Index (RSI)
- MGEE 46.94
- RYTM 82.22
- Support Level
- MGEE $86.99
- RYTM $64.65
- Resistance Level
- MGEE $90.14
- RYTM $67.75
- Average True Range (ATR)
- MGEE 1.91
- RYTM 2.88
- MACD
- MGEE -0.01
- RYTM 1.71
- Stochastic Oscillator
- MGEE 33.33
- RYTM 99.82
About MGEE MGE Energy Inc
MGE Energy provides electric service to 161,000 customers and natural gas service to 173,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings. MGE's generation mix is 40% coal, 21% renewable energy, 17% natural gas, and third-party purchased power.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.